Jill Wechsler, Pharm Exec’s Washington Correspondent

Recent lawsuits are challenging the constitutionality of provisions in the Inflation Reduction Act.

Pandemic preparedness and curbing PBMs among the pending legislation that will have to wait until after summer recess.

The agency proposes significant revisions to oversight programs for drugs and medical products.

The confirmatory study—which tracked 18 months of data—helped clear the way for new Alzheimer’s drug.

Could feel the impact from potential new provisions to legislation reauthorizing US international health programs.

Indicates that reimbursement for new slate of Alzheimer’s treatments will occur only with the completion of studies to support full approval.